Clinical trial
Long-term Effects of Semaglutide on Diabetic Retinopathy in Subjects With Type 2 Diabetes
NCT03811561 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Long-term Effects of Semaglutide on Diabetic Retinopathy in Subjects With Type 2 Diabetes
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- May 8, 2019
- Completion date
- November 7, 2027
- Enrollment
- 1,500 (estimated)
- Sites
- 230
Conditions
As the registry lists them; a condition with its own page is linked.